Verrica Pharmaceuticals (NASDAQ:VRCA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Thursday.

According to Zacks, “Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company. It develops and manufactures pharmaceutical products for the treatment of skin diseases such as molluscum contagiosum and dermatology. Verrica Pharmaceuticals, Inc. is based in PA, United States. “

Shares of VRCA opened at $10.25 on Thursday. Verrica Pharmaceuticals has a 1-year low of $10.03 and a 1-year high of $23.29.

Verrica Pharmaceuticals (NASDAQ:VRCA) last released its quarterly earnings data on Wednesday, November 7th. The company reported ($0.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.03). Equities analysts expect that Verrica Pharmaceuticals will post -1.17 earnings per share for the current year.

In related news, COO Linda Palczuk acquired 2,500 shares of Verrica Pharmaceuticals stock in a transaction on Monday, September 17th. The stock was purchased at an average cost of $16.52 per share, with a total value of $41,300.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Paul B. Manning acquired 70,200 shares of Verrica Pharmaceuticals stock in a transaction on Tuesday, November 13th. The shares were bought at an average cost of $14.15 per share, with a total value of $993,330.00. The disclosure for this purchase can be found here.

Hedge funds have recently added to or reduced their stakes in the business. Fosun International Ltd bought a new position in Verrica Pharmaceuticals during the second quarter worth $15,705,000. Asymmetry Capital Management L.P. boosted its position in Verrica Pharmaceuticals by 28.1% during the third quarter. Asymmetry Capital Management L.P. now owns 76,885 shares of the company’s stock worth $1,249,000 after purchasing an additional 16,885 shares during the period. Dean Capital Investments Management LLC bought a new stake in shares of Verrica Pharmaceuticals in the second quarter valued at about $676,000. Gilder Gagnon Howe & Co. LLC boosted its position in shares of Verrica Pharmaceuticals by 12.4% in the third quarter. Gilder Gagnon Howe & Co. LLC now owns 167,574 shares of the company’s stock valued at $2,723,000 after acquiring an additional 18,530 shares during the period. Finally, FMR LLC bought a new stake in shares of Verrica Pharmaceuticals in the second quarter valued at about $21,703,000. 32.07% of the stock is owned by hedge funds and other institutional investors.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790.

Further Reading: What is a stock buyback?

Get a free copy of the Zacks research report on Verrica Pharmaceuticals (VRCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.